● pepmg Research Desk · Peer-reviewed evidence review
What the research says about hexarelin
A neutral summary of the peer-reviewed literature on hexarelin, a synthetic growth-hormone-releasing peptide studied mainly in short human neuroendocrine experiments and in animal cardiovascular models. Research use only.
Moderate evidence — Limited human trials — often early-phase. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Hexarelin is a synthetic growth-hormone-releasing peptide (GHRP) that acts on the growth-hormone-secretagogue receptor to trigger release of the body's own growth hormone; most human data come from small, short pharmacology studies of that hormonal response [1][2].
- In controlled crossover studies in healthy men, an intravenous bolus of hexarelin produced a greater peak growth-hormone response than growth-hormone-releasing hormone (GHRH), and the two given together were more than additive [2][3].
- Its cardiovascular effects (via the CD36 receptor) have been studied mostly in animals and cell models, where hexarelin reduced post-infarction mortality and dysfunction; in one ghrelin-knockout-mouse study 2-week mortality was 6.7% on hexarelin versus 50% on vehicle [4][6].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What hexarelin is
Hexarelin is described in the literature as a synthetic six-amino-acid peptide belonging to the growth-hormone-releasing peptide (GHRP) family. GHRPs have no structural homology with growth-hormone-releasing hormone (GHRH); they act through their own specific receptor, the growth-hormone-secretagogue receptor (GHSR), whose natural ligand is ghrelin, to stimulate the pituitary to release growth hormone [1]. Hexarelin is reported to be chemically more stable and functionally more potent than ghrelin itself [6].
Hexarelin has never been an approved medicine. It was investigated in the 1990s and 2000s as a probe of pituitary function and as a candidate growth-hormone secretagogue, and more recently as a tool for studying receptors in the heart and blood vessels. Material sold by research-chemical vendors is not an approved pharmaceutical product and is offered for laboratory and research use only.
What the human research has measured
Moderate evidenceThe human hexarelin literature is made up largely of small, acute, single-dose neuroendocrine experiments in healthy volunteers or selected patients, measuring the growth-hormone response to an intravenous bolus rather than any long-term clinical outcome. In a randomized crossover study in healthy adult men, the peak serum growth-hormone response to hexarelin was greater than the response to GHRH [2]. A separate crossover study in normal adults reported that hexarelin elicited a marked growth-hormone release that was significantly higher than GHRH, and that combining the two produced a further increase [3].
Other controlled work examined how the response behaves under different physiological conditions: hexarelin still released growth hormone in patients with a raised somatostatin tone from chronic glucocorticoid excess [5], and its interaction with somatostatin and GHRH was mapped in infusion studies [7]. Because hexarelin also drives release of prolactin and of ACTH and cortisol, it was tested as a dynamic test of pituitary reserve in people with pituitary disease [8].
These studies establish that hexarelin releases growth hormone in humans and characterize the hormonal pharmacology. They were not designed to test whether hexarelin improves body composition, athletic performance, or any disease outcome, and no large or long-term controlled human trials of those endpoints appear in this corpus.
What the cardiovascular and preclinical work has measured
Preclinical onlyA distinct line of research concerns effects on the heart and blood vessels that appear to be independent of growth-hormone release. Hexarelin binds the scavenger receptor CD36 in cardiac tissue, and reviews describe this as the route for direct cardioprotective actions [6]. Most of this evidence is in animal and cell models.
In genetically obese Zucker rats, chronic hexarelin treatment was reported to improve growth-hormone secretion and to protect against post-ischemic ventricular dysfunction [9]. In a study using ghrelin-knockout mice given a coronary-artery ligation, two-week mortality was significantly lower with hexarelin (6.7%) and with ghrelin (14.3%) than with vehicle (50%), and cardiac function after infarction was better in the treated animals [4]. These are findings in animals and cells; they have not been confirmed in controlled human cardiovascular trials in this corpus.
What the studies report on safety and adverse events
Moderate evidenceThe human hexarelin studies were short, acute pharmacology experiments, and the abstracts emphasize the compound's hormonal cross-reactivity rather than tabulated adverse-event rates. A recurring theme is that hexarelin and other GHRPs are not selective for growth hormone: they also stimulate release of prolactin and of ACTH and cortisol through combined hypothalamic and direct pituitary mechanisms [8][10]. This lack of hormonal selectivity is exactly why hexarelin was studied as a test of pituitary reserve, and it is a relevant consideration for any use outside a controlled test [8].
Repeated administration has been examined because the growth-hormone response can change with successive doses; controlled studies specifically looked at the response to two consecutive boluses and at whether the effect is sustained over time [3]. The corpus does not contain long-term human safety trials of hexarelin, so there is no controlled evidence here on the consequences of chronic use.
None of this is a safety guarantee. Material sold by research-chemical vendors is not an approved pharmaceutical product, is not manufactured to pharmacy standards, and has not been through the controlled long-term safety evaluation an approved drug requires. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence base is characterized as moderate and narrow: multiple small, randomized, crossover pharmacology studies in humans consistently show that hexarelin releases growth hormone [2][3], but they measured that hormonal response over minutes to hours, not clinical outcomes over time. The cardiovascular and metabolic claims most often attached to hexarelin rest largely on animal and cell studies [4][6][9]. "Moderate" here describes the presence of controlled human pharmacology, not proof of any therapeutic benefit, and the scope is important: most human work is decades old and focused on neuroendocrine testing.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 10
- Growth hormone-releasing peptides.
- Hexarelin induced growth hormone release is influenced by exogenous growth hormone.
- GH responsiveness to repeated GHRH or hexarelin administration in normal adults.
- Hexarelin treatment in male ghrelin knockout mice after myocardial infarction.
- Comparison of the effects of growth hormone-releasing hormone and hexarelin in patients with glucocorticoid excess.
- The cardiovascular action of hexarelin.
- Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
- Hexarelin as a test of pituitary reserve in patients with pituitary disease.
- Endocrine, metabolic and cardioprotective effects of hexarelin in obese Zucker rats.
- Growth hormone-releasing peptides and the cardiovascular system.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.